Shots:
- EirGenix has partnered with Sandoz to commercialize EG1206A, a biosimilar to Roche’s Perjeta (Pertuzumab), globally excl. Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, & Japan
- As per the deal, EirGenix will handle product development, manufacturing, & supply, receiving ~$152M in upfront & milestone payments, profit share post-launch in licensed regions, & additional sales-based incentives
- EG1206A has completed its PK study & received positive feedback from the FDA & EMA, granting a waiver for P-III efficacy trials. The partners also have a global deal for EG12014 (150 & 420mg), a biosimilar to Trastuzumab, with BLA under the FDA’s review
Ref: PRnewswire| Image: EirGenix & Sandoz | Press Release
Related News:- Minze Health Partners with Medtronic to Expand Digital Bladder Monitoring Across EMEA
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
